H

hVIVO Services Limited | Queen Mary BioEnterprises Innovation Centre

Research site
(Unclaimed)
Location
42 New Road, London, London, City of, England
Site insights

Top conditions

Human Influenza (5 trials)

Respiratory Syncytial Virus Infections (4 trials)

Virus Diseases (3 trials)

Infections (3 trials)

Communicable Diseases (1 trial)

Top treatments

Neumifil
CC-42344
JNJ-64281802
EDP-323
JNJ-64417184
Palivizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

3 of 12
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

A randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of o...

Enrolling
RSV Infection
Drug: EDP-323 Dose Regimen 1
Drug: Placebo

Participants in this study will be given either CC-42344 (one of two dose levels) or placebo orally for 5 days after receiving an influenza (flu) cha...

Enrolling
Influenza A
Drug: Placebo
Drug: CC-42344

Healthy adult participants will be challenged with the H1N1 Influenza virus and then treated with either SAB-176 or placebo.

Active, not recruiting
Influenza A H1N1
Other: Placebo
Biological: SAB-176

Trial sponsors

Bavarian Nordic logo

Bavarian Nordic (1 trial)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems